The review provides a thorough overview of cannabinoid-based therapies, but I found one aspect particularly intriguing: the pharmacological synergy between cannabinoids and opioids for pain management. The article notes a reduction in opioid use with concurrent cannabinoid administration but does not elaborate on the potential mechanisms behind this interaction. Could the authors clarify whether this synergy is mediated primarily through receptor crosstalk (e.g., CB1-opioid receptor interactions) or if it involves broader systemic effects, such as changes in inflammatory pathways or neurotransmitter modulation?
Additionally, given the concerns around variability in cannabinoid formulations (e.g., inconsistent CBD:THC ratios), how do the authors envision improving standardization to ensure clinical reproducibility? Addressing this could significantly enhance the practical implications of cannabinoid-based treatments for a range of conditions.